C61
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. ECOG Performance Status 0 or 1 2. informed concent 3. prostate cancer (<cT3, PSA<20 ng/ml, Gleason-Score<8) 4. ability to read and answer German questionnaires
Exclusion criteria
Exclusion criteria: 1. Medical reasons against one of the therapies 2. Other treatments of prostate cancer 3. Metastases 4. Life expectancy < 5 years 5. Patients with legal guardian 6. Participation in other studies that could influence the results 7. Cardiac pacemaker
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life after treatment and after 2 weks, 3, 6, 9 and 12 month. Questionnaires: EORTC-C30, EORTC-PR25, ICS, IIEF5, PHQ, CCAT-P. | — |
Secondary
| Measure | Time frame |
|---|---|
| Before, directly after and 2 weeks, 3 month, 6 month ans 1 year after treatment: Biochemical relapse-free prostate-specific survival Side effects (ICS, IIEF5) Depression (PHQ) Anxiety (PHQ) Contentment (Distress-scale, CCAT-P, interview) fear of progression (PA-F-KF) Contentment of spouse (Distress-scale, EPIC, PHQ, interview) | — |
Countries
Germany
Contacts
Urologische Universitätsklinik